Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10763246 | 0.85 | CA1 (0.52) | KMT2AMEN1PKMALDH1A1CA12 | |
| SCHEMBL31008437 | 0.85 | CA1 (0.52) | KMT2AMEN1PKMALDH1A1CA12 | |
| SCHEMBL8953032 | 0.85 | ALDH1A1 (0.45) | KMT2ARAB9AMEN1PKMALDH1A1 | |
| SCHEMBL5461908 | 0.81 | SMN1; SMN2 (0.64) | KMT2ARAB9AMEN1ALDH1A1CA12 | |
| SCHEMBL12317500 | 0.80 | CYP1A2 (0.44) | KMT2ARAB9AMEN1ALDH1A1NPC1 | |
| SCHEMBL28043705 | 0.80 | POLB (0.65) | KMT2ARAB9AMEN1PKMALDH1A1 | |
| SCHEMBL5457643 | 0.78 | EGFR (0.47) | RAB9AALDH1A1KDM4EKDM5A | |
| SCHEMBL24784811 | 0.77 | KMT2A (0.57) | KMT2ARAB9AMEN1PKMALDH1A1 | |
| SCHEMBL730081 | 0.77 | KMT2A (0.57) | KMT2ARAB9AMEN1PKMALDH1A1 | |
| SCHEMBL30772316 | 0.77 | KMT2A (0.67) | KMT2ARAB9AMEN1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002539450-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1163518-A2 | ELISA KIT FOR THE DETERMINATION OF METABOLIC PHENOTYPES | Leyland-Jones, Brian (CA) | 2001-12-19 | — | — | EP | claimed |
| WO-2000055624-A2 | ELISA KIT FOR THE DETERMINATION OF METABOLIC PHENOTYPES | LEYLAND JONES BRIAN (CA) | 2000-09-21 | — | — | WO | claimed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-8450506-B2 | Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2013-05-28 | — | — | US | disclosed |
| US-8450506-B2 | Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2013-05-28 | — | — | US | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| EP-0891365-B1 | BENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSES | UNIV CALIFORNIA (US) | 2002-10-16 | — | — | EP | disclosed |
| US-5962447-A | PSYCHOLOGICAL DISORDERS, COGNITION ACTIVATORS, SCHIZOPHRENIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0891365-A1 | BENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5736543-A | COGNITION ACTIVATORS/NOOTROPIC AGENTS WHICH STIMULATE A-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONATE (AMPA) RECEPTORS IN BRAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997036907-A9 | BENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSE | — | 1997-12-04 | — | — | WO | disclosed |
| WO-1997036907-A1 | BENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KMT2A 1886/4885RAB9A 2721/4885MEN1 511/4885 |
| US-20120316230-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | KMT2A 4340/4885RAB9A 2608/4885MEN1 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.